Volume 25, Number 1—January 2019
Synopsis
Clinical and Radiologic Characteristics of Human Metapneumovirus Infections in Adults, South Korea
Hyun Jung Koo, Han Na Lee, Sang-Ho Choi, Heungsup Sung, Hwa Jung Kim, and Kyung-Hyun Do
Table 1
Clinical characteristics of patients infected with human metapneumovirus, South Korea*
| Characteristic | Immunocompetent | Solid tumors† | SOT | HCT | HM | Steroid use | Total |
|---|---|---|---|---|---|---|---|
| Total |
459 (54) |
174 (20) |
59 (7) |
9 (1) |
58 (7) |
90 (11) |
849 |
| Age, y |
67 (56–75) |
62 (53–70) |
56 (49–62) |
54 (32–63) |
60 (47–67) |
67 (52–75) |
64 (53–73) |
| Sex | |||||||
| M | 229 (50) | 89 (51) | 25 (42) | 6 (67) | 24 (41) | 50 (56) | 442 (52) |
| F | 230 (50) | 85 (49) | 34 (58) | 3 (33) | 34 (59) | 40 (44) | 407 (48) |
| Smoking status | |||||||
| Never | 326 (71) | 104 (60) | 43 (73) | 5 (56) | 40 (69) | 47 (52) | 565 (67) |
| Former | 99 (22) | 63 (36) | 16 (27) | 3 (33) | 14 (24) | 38 (42) | 233 (6) |
| Current |
34 (7) |
7 (4) |
0 |
1 (11) |
4 (7) |
5 (6) |
51 (27) |
| BP, mm Hg | |||||||
| Systolic | 134 (120–152) | 124 (115–137) | 131 (116–146) | 130 (113–136) | 128 (120–140) | 134 (120–151) | 131 (119–147) |
| Diastolic |
80 (73–90) |
80 (73–88) |
82 (74–92) |
88 (82–90) |
82 (76–90) |
82 (74–90) |
80 (73–90) |
| Temperature, °C | 36.6 (36.4–37.2) | 36.6 (36.4–37.2) | 36.4 (36.2–36.8) | 36.7 (36.5–37.7) | 36.5 (36.2–36.7) | 36.6 (36.3–36.9) | 36.6 (36.4–37.1) |
| Temperature, >37°C |
70 (15) |
25 (14) |
4 (7) |
3 (33) |
5 (9) |
16 (18) |
123 (14.5) |
| Heart rate, beats/min | 83 (70–99) | 88 (78–103) | 82 (73–91) | 100 (90–110) | 87 (77–100) | 93 (84–106) | 87 (74–100) |
| Respiratory rate, breaths/min |
20 (18–22) |
20 (18–20) |
18 (18–20) |
22 (20–27) |
20 (18–22) |
22 (20–24) |
20 (18–22) |
| Body mass index, kg/m2 | 23.2 (20.4–25.9) | 23.1 (20.3–25.5) | 23.2 (21.3–25.1) | 20.2 (17.0–25.1) | 22.4 (20.5–25.2) | 22.6 (20.2–24.4) | 23.1 (20.4–25.5) |
| Hypertension | 239 (52) | 71 (41) | 47 (80) | 3 (33) | 22 (38) | 51 (57) | 433 (51) |
| Diabetes mellitus |
157 (34) |
42 (24) |
44 (75) |
4 (44) |
20 (35) |
29 (32) |
296 (35) |
| Location of patients‡ | |||||||
| Outpatient clinic | 22 | 1 | 2 | 0 | 0 | 2 | 27 |
| Hospitalized | 131 | 137 | 21 | 3 | 24 | 35 | 351 |
| ED |
306 |
36 |
36 |
6 |
34 |
53 |
471 |
| Type of infection | |||||||
| CA | 415 (90) | 150 (86) | 51 (86) | 7 (88) | 47 (81) | 84 (93) | 756 (89) |
| Nosocomial |
44 (10) |
24 (14) |
8 (14) |
2 (22) |
11 (19) |
6 (7) |
93 (11) |
| URI | 126 (28) | 68 (39) | 30 (51) | 1 (11) | 20 (35) | 27 (30) | 270 (32) |
| LRD |
333 (73) |
106 (61) |
29 (49) |
8 (89) |
38 (66) |
63 (70) |
579 (68) |
| Initial CRP level at hospital admission, mg/L |
4.3
(1.5–9.9) |
6.5
(2.6–13.3) |
4.6
(1.0–7.7) |
10.6
(5.5–19.7) |
5.8
(2.8–12.0) |
4.4
(1.9–4.4) |
4.9
(1.8–11.0) |
| Leukocyte count at diagnosis, × 103/μL | 7.7 (5.5–10.5) | 5.4 (2.8–8.7) | 8.5 (4.8–10.6) | 12.0 (6.5–13.6) | 4.8 (2.3–7.4) | 8.3 (5.7–11.5) | 7.2 (4.9–10.3) |
| >10 | 128 (28) | 33 (19) | 16 (27) | 5 (56) | 7 (12) | 34 (38) | 223 (26) |
| <10 |
331 (72) |
141 (81) |
43 (73) |
4 (44) |
51 (88) |
56 (62) |
626 (74) |
| Neutrophil count at diagnosis, × 103/μL§ | 5.5 (3.4–8.3) | 3.9 (1.7–6.5) | 6.1 (3.3–8.5) | 7.9 (5.9–9.5) | 2.9 (1.3–5.1) | 6.2 (3.9–9.6) | 5.1 (3.0–8.1) |
| >5.0 | 252 (55) | 67 (39) | 35 (59) | 6 (67) | 14 (24) | 56 (62) | 430 (51) |
| <5.0 |
205 (45) |
106 (61) |
24 (41) |
1 (11) |
42 (72) |
32 (36) |
410 (48) |
| Lymphocyte count at diagnosis, × 103/μL§ | 1.3 (0.9–1.8) | 0.8 (0.5–1.3) | 1.0 (0.6–1.4) | 2.9 (0.7–4.2) | 0.8 (0.4–1.7) | 1.1 (0.7–1.6) | 1.1 (0.7–1.6) |
| >0.7 | 380 (83) | 97 (56) | 41 (70) | 5 (56) | 33 (57) | 65 (72) | 621 (73) |
| <0.7 |
77 (17) |
76 (44) |
18 (31) |
2 (22) |
23 (40) |
23 (26) |
219 (26) |
| Platelet count, × 103/μL |
193
(145–243) |
149
(101–223) |
166
(116–231) |
82
(35–187) |
86
(36–146) |
198
(143–245) |
176
(124.5–233) |
| Blood urea nitrogen, mg/Dl | 14 (10–22) | 13 (9–19) | 21 (14–31) | 15.0 (8.5–27.0) | 14.5 (10–20.3) | 15 (11–23.5) | 14.0 (10.0–21.0) |
| Creatinine, mg/dL | 0.8 (0.7–1.1) | 0.8 (0.6–1.0) | 1.3 (1.0–1.8) | 0.9 (0.7–1.4) | 0.8 (0.6–1.2) | 0.8 (0.6–1.1) | 0.8 (0.7–1.1) |
| Procalcitonin, ng/mL | 0.2 (0.1–1.2) | 0.2 (0.1–0.7) | 0.2 (0.1–1.2) | 0.2 (0.1–1.1) | 0.2 (0.1–0.6) | 0.2 (0.1–0.9) | 0.2 (0.1–0.9) |
*Values are no. (%) or median (interquartile range) unless otherwise indicated. BP, blood pressure; CA, community acquired; CRP, C-reactive protein; ED, emergency department; HCT, hematologic stem cell transplantation; HM, hematologic malignancy; HMPV, human metapneumovirus; LRD, lower respiratory tract disease; SOT, solid organ transplants; URI, upper respiratory tract infection.
†Patients with solid tumors were given chemotherapy within 6 mo.
‡Locations at which patients were tested for HMPV.
§Detailed laboratory results, including neutrophil and lymphocyte counts, were unavailable for 9 patients who visited outpatient clinics
Page created: December 18, 2018
Page updated: December 18, 2018
Page reviewed: December 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.